Diagnosis and management of valvular aortic stenosis

Research output: Contribution to journalArticle

Abstract

Valvular aortic stenosis (AS) is a progressive disease that affects 2% of the population aged 65 years or older. The major cause of valvular AS in adults is calcification and fibrosis of a previously normal tricuspid valve or a congenital bicuspid valve, with rheumatic AS being rare in the United States. Once established, the rate of progression of valvular AS is quite variable and impossible to predict for any particular patient. Symptoms of AS are generally insidious at onset, though development of any of the three cardinal symptoms of angina, syncope, or heart failure portends a poor prognosis. Management of symptomatic AS remains primarily surgical, though transcatheter aortic valve replacement (TAVR) is becoming an accepted alternative to surgical aortic valve replacement (SAVR) for patients at high or prohibitive operative risk.

Original languageEnglish (US)
Pages (from-to)15-24
Number of pages10
JournalClinical Medicine Insights: Cardiology
Volume8
DOIs
StatePublished - Oct 19 2014

Fingerprint

Aortic Valve Stenosis
Tricuspid Valve
Syncope
Aortic Valve
Mitral Valve
Surgical Instruments
Fibrosis
Heart Failure
Population

Keywords

  • Aortic stenosis therapy
  • Balloon aortic valvuloplasty
  • Surgical aortic valve replacement
  • Transcatheter aortic valve replacement
  • Valvular aortic stenosis

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Diagnosis and management of valvular aortic stenosis. / Czarny, Matthew; Resar, Jon R.

In: Clinical Medicine Insights: Cardiology, Vol. 8, 19.10.2014, p. 15-24.

Research output: Contribution to journalArticle

@article{80f5c2759c724df3a46ee79ea348cdef,
title = "Diagnosis and management of valvular aortic stenosis",
abstract = "Valvular aortic stenosis (AS) is a progressive disease that affects 2{\%} of the population aged 65 years or older. The major cause of valvular AS in adults is calcification and fibrosis of a previously normal tricuspid valve or a congenital bicuspid valve, with rheumatic AS being rare in the United States. Once established, the rate of progression of valvular AS is quite variable and impossible to predict for any particular patient. Symptoms of AS are generally insidious at onset, though development of any of the three cardinal symptoms of angina, syncope, or heart failure portends a poor prognosis. Management of symptomatic AS remains primarily surgical, though transcatheter aortic valve replacement (TAVR) is becoming an accepted alternative to surgical aortic valve replacement (SAVR) for patients at high or prohibitive operative risk.",
keywords = "Aortic stenosis therapy, Balloon aortic valvuloplasty, Surgical aortic valve replacement, Transcatheter aortic valve replacement, Valvular aortic stenosis",
author = "Matthew Czarny and Resar, {Jon R}",
year = "2014",
month = "10",
day = "19",
doi = "10.4137/CMC.S15716",
language = "English (US)",
volume = "8",
pages = "15--24",
journal = "Clinical Medicine Insights: Cardiology",
issn = "1179-5468",
publisher = "Libertas Academica Ltd.",

}

TY - JOUR

T1 - Diagnosis and management of valvular aortic stenosis

AU - Czarny, Matthew

AU - Resar, Jon R

PY - 2014/10/19

Y1 - 2014/10/19

N2 - Valvular aortic stenosis (AS) is a progressive disease that affects 2% of the population aged 65 years or older. The major cause of valvular AS in adults is calcification and fibrosis of a previously normal tricuspid valve or a congenital bicuspid valve, with rheumatic AS being rare in the United States. Once established, the rate of progression of valvular AS is quite variable and impossible to predict for any particular patient. Symptoms of AS are generally insidious at onset, though development of any of the three cardinal symptoms of angina, syncope, or heart failure portends a poor prognosis. Management of symptomatic AS remains primarily surgical, though transcatheter aortic valve replacement (TAVR) is becoming an accepted alternative to surgical aortic valve replacement (SAVR) for patients at high or prohibitive operative risk.

AB - Valvular aortic stenosis (AS) is a progressive disease that affects 2% of the population aged 65 years or older. The major cause of valvular AS in adults is calcification and fibrosis of a previously normal tricuspid valve or a congenital bicuspid valve, with rheumatic AS being rare in the United States. Once established, the rate of progression of valvular AS is quite variable and impossible to predict for any particular patient. Symptoms of AS are generally insidious at onset, though development of any of the three cardinal symptoms of angina, syncope, or heart failure portends a poor prognosis. Management of symptomatic AS remains primarily surgical, though transcatheter aortic valve replacement (TAVR) is becoming an accepted alternative to surgical aortic valve replacement (SAVR) for patients at high or prohibitive operative risk.

KW - Aortic stenosis therapy

KW - Balloon aortic valvuloplasty

KW - Surgical aortic valve replacement

KW - Transcatheter aortic valve replacement

KW - Valvular aortic stenosis

UR - http://www.scopus.com/inward/record.url?scp=84941127989&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84941127989&partnerID=8YFLogxK

U2 - 10.4137/CMC.S15716

DO - 10.4137/CMC.S15716

M3 - Article

VL - 8

SP - 15

EP - 24

JO - Clinical Medicine Insights: Cardiology

JF - Clinical Medicine Insights: Cardiology

SN - 1179-5468

ER -